Dermapharm Holding SE represents a set of core values and a corporate philosophy that defines its operations. The company strives for excellence through continuous innovation and development of high-quality pharmaceutical products. Dermapharm Holding values integrity, reliability, and responsibility towards its customers, shareholders, employees, and partners. With a focus on sustainability and social responsibility, the company is committed to contributing to the well-being of society and the environment. By combining expertise, entrepreneurial vision, and a customer-centric approach, Dermapharm Holding SE aims to deliver exceptional healthcare solutions while fostering long-term success and growth.

Dermapharm Holding SE, a renowned pharmaceutical company, has a widespread presence primarily in Germany. As a leading player in the German market, Dermapharm has established a strong foothold, catering to the healthcare needs of millions of people across the country. With its headquarters located in Grünwald, Germany, Dermapharm focuses on developing, manufacturing, and distributing various pharmaceutical products, including both prescription and over-the-counter medications. Leveraging its extensive network and expertise, Dermapharm continues to expand its reach beyond Germany, aiming to broaden its presence and deliver high-quality pharmaceutical solutions to customers in other European countries and regions as well.

Dermapharm Holding SE, a renowned pharmaceutical company, has accomplished several notable milestones. The company has successfully expanded its product portfolio, offering a diverse range of high-quality pharmaceuticals and health-related products. Dermapharm aims at driving growth and innovation through strategic acquisitions and partnerships, expanding its market presence both nationally and internationally. The company has consistently achieved robust financial results, demonstrating its strong performance and market resilience. Dermapharm Holding SE has also demonstrated its commitment to sustainability, implementing environmentally friendly practices throughout its operations. Through its continuous dedication to excellence, Dermapharm Holding SE has positioned itself as a leading player in the pharmaceutical industry.

Dermapharm Holding SE is a German pharmaceutical company that specializes in the development and production of various medical products. Founded in 1991, Dermapharm has grown to become one of the leading manufacturers of pharmaceuticals in Germany. The company offers a broad portfolio of prescription and over-the-counter drugs, as well as dietary supplements and herbal medicines. With a strong focus on research and development, Dermapharm aims to continually innovate and provide effective solutions for various therapeutic areas. With its vast experience and high-quality standards, Dermapharm Holding SE has established itself as a trusted name in the pharmaceutical industry.

The main competitors of Dermapharm Holding SE in the market are prominent pharmaceutical companies such as Hexal AG, Stada Arzneimittel AG, and Dr. Reddy's Laboratories Ltd. These competitors engage in similar activities in the pharmaceutical industry and present a significant challenge to Dermapharm Holding SE. Their presence drives competition, fostering innovation and improving product quality. As a leading stock in the industry, Dermapharm Holding SE consistently adapts its strategies to stay ahead of its competitors and deliver value to its shareholders.

Dermapharm Holding SE is primarily active in the pharmaceutical industry.

The business model of Dermapharm Holding SE revolves around the development, production, and distribution of pharmaceutical products. As a leading manufacturer of both branded and generic medications, Dermapharm focuses on a diverse range of therapeutic areas, including dermatology, respiratory diseases, and women's health. The company aims to provide high-quality pharmaceutical solutions to patients and healthcare professionals worldwide. By investing in research and development, Dermapharm continuously innovates its product portfolio to address evolving market demands. With a strong distribution network and strategic partnerships, Dermapharm ensures the availability and accessibility of its pharmaceuticals, contributing to the health and well-being of individuals globally.

P/E santykio šiuo metu Dermapharm Holding apskaičiuoti negalima.

KUV šiuo metu negali būti apskaičiuotas Dermapharm Holding.

AlleAktien kokybės įvertis Dermapharm Holding yra 2/10.

Pajamos šiuo metu negali būti apskaičiuotos Dermapharm Holding.

Pelnas šiuo metu negali būti apskaičiuotas Dermapharm Holding.

Dermapharm Holding SE is a leading company in the pharmaceutical industry that manufactures and distributes prescription and over-the-counter branded products, generics, and specialty medicines. The company offers a wide range of more than 2500 products, providing innovative solutions for various therapy areas such as dermatology, gynecology, neurology, pain management, urology, and more. The business model of Dermapharm is based on four core areas: 1. Branded products: Dermapharm has developed an extensive portfolio of branded products used in various therapy areas. Some of the best-known ones include Betadona® for disinfection of the skin and mucous membranes, Excipial® for the care of dry, cracked skin, and Allpresan® for the treatment of foot problems. The company is constantly searching for new innovative product ideas and regularly invests in research and development. 2. Generics: Dermapharm also produces and distributes a wide range of generics. These are typically much cheaper than branded products, providing customers with affordable access to important medicines. By manufacturing generics, the company also contributes to making healthcare more accessible for all. 3. Development of specialty medicines: Dermapharm specializes in the development of specialty medicines for niche indications. This includes preparations for the treatment of rare diseases or medications adapted for specific patient groups. Through its focus on these niche markets, the company has built a strong position and created a unique selling proposition. 4. International expansion: In addition to the German market, Dermapharm is also present in other European countries and plans to expand its business globally. The company focuses on targeted expansion and has already formed strategic partnerships in some countries. Overall, Dermapharm's business model is based on a combination of innovative products, high manufacturing expertise, and a strong distribution network. Digitalization also plays an important role, with the company investing in the use of modern technologies to optimize its business processes and create new digital business models. In summary, Dermapharm's business model offers customers access to a wide range of medicines from various therapy areas. The company aims to expand its market share and develop innovative products for the future.

Dermapharm Holding moka dividendą 0 EUR, kuris yra paskirstytas per 1 išmokas per metus.

„Dermapharm Holding moka dividendus 1 kartus per metus.“

Dermapharm Holding ISIN yra DE000A2GS5D8.

Dermapharm Holding WKN yra A2GS5D.

Dermapharm Holding akcijų simbolis yra DMP.DE.

Per paskutinius 12 mėnesių Dermapharm Holding išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams Dermapharm Holding tikėtina išmokės dividendus, kurie sudarys 1,14 EUR.

Dermapharm Holding šiuo metu yra dydžio dividendų grąža.

Dermapharm Holding moka dividendus kas ketvirtį. Jie išmokami liepa, liepa, liepa, liepa mėnesiais.

Dermapharm Holding per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 1,14 EUR. Tai atitinka 3,02 % dividendų grąžos procentą.

Dermapharm Holding priskiriamas sektoriui "Sveikata".

Norėdamas gauti paskutinį Dermapharm Holding dividendą nuo 2024-07-02, kurio dydis yra 0,88 EUR, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2024-06-28.

Paskutinės dividendų išmokėjimas įvyko 2024-07-02.

2023 metais Dermapharm Holding išmokėjo 2,17 EUR dividendų.

Dermapharm Holding dividendai yra mokami EUR.